Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Value Partners Group
Deal Size : $110.0 million
Deal Type : Series E Financing
Insilico Gains $110M Series E for AI-Driven Drug Discovery
Details : The financing aims to fund the clinical development of company's lead product INS018_055. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : INS018_055
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Value Partners Group
Deal Size : $110.0 million
Deal Type : Series E Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Stemline Therapeutics
Deal Size : $570.0 million
Deal Type : Licensing Agreement
Menarini & Insilico Medicine Sign Global License for AI-Discovered Oncology Asset
Details : Under the licensing agreement, Stemline will hold the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
January 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Stemline Therapeutics
Deal Size : $570.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ISM5411
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insilico Announces Positive Results from Phase 1 Trials of ISM5411 for IBD
Details : ISM5411 is a novel gut-restricted and PHD specific Inhibitor, beig investigated for the treatment for Inflammatory Bowel Disease (IBD).
Product Name : ISM5411
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : ISM5411
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ISM001-055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
After phase 2 data, Insilico plots pivotal lung disease trial
Details : ISM001-055, a small molecule developed using generative AI to target TNIK (Traf2- and NCK- interacting kinase). It is being investigated for idiopathic pulmonary fibrosis.
Product Name : ISM001-055
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : ISM001-055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Stemline Therapeutics
Deal Size : $512.0 million
Deal Type : Licensing Agreement
Menarini Group Signs Exclusive License for KAT6 Inhibitor for Breast Cancer
Details : Stemline will have global rights to develop a novel KAT6A inhibitor designed using Insilico’s AI platform, targeting hormone-sensitive cancers and other oncology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $12.0 million
April 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Stemline Therapeutics
Deal Size : $512.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ISM3091
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, a best-in-class small molecule inhibitor of USP1, as a synthetic lethal target in the context of BRCA-mutated tumors, and other USP1-targ...
Product Name : ISM3091
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : ISM3091
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INS018_055 is the first anti-fibrotic small molecule inhibitor, generated by Insilico's Pharma.AI drug discovery platform, which targets major activated signaling cascades that significantly contribute to the pathogenesis idiopathic pulmonary fibrosis.
Product Name : INS018_055
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ISM3312
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
Details : ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform for the treatment of COVID-19.
Product Name : ISM3312
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : ISM3312
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,221.5 million
Deal Type : Collaboration
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
Details : Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,221.5 million
Deal Type : Collaboration
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : BHR Partners
Deal Size : $60.0 million
Deal Type : Series D Financing
Details : Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma...
Product Name : INS018_055
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 06, 2022
Lead Product(s) : INS018_055
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : BHR Partners
Deal Size : $60.0 million
Deal Type : Series D Financing